The expression of Bcl-2 antiapoptotic proteins is upregulated in hematological malignancies, including leukemia [62], and several studies have been conducted to exploit those proteins as possible targets for drug development [63], with some inhibitors of the Bcl-2 family already being approved for leukemia treatment [64,65]. This evidence concerns the gene BCL2 and leukemia.